Form4insider filings, from the source

SEC Form 4 · accession 0000899243-17-028424

Ocera Therapeutics, Inc. · OCRX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Linda S Grais
Officer — President and CEO · Director
Period of report
Dec 11, 2017
Accepted (ET)
Dec 11, 2017 · 3:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001274644

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2,F3Dec 11, 2017D230,000$1.52D0D
Common StockF1,F2Dec 11, 2017D70,000$1.52D0D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (Right to Buy)F4,F5,F6$2.15Dec 11, 2017D289,200D—Dec 14, 2026Common Stock289,2000D
Stock Option (Right to Buy)F4,F5,F7$2.98Dec 11, 2017D348,600D—Jan 5, 2026Common Stock348,6000D
Stock Option (Right to Buy)F4,F5,F8$3.76Dec 11, 2017D160,000D—Jun 17, 2025Common Stock160,0000D
Stock Option (Right to Buy)F4,F5,F9$7.38Dec 11, 2017D491,550D—Aug 13, 2023Common Stock491,5500D
Stock Option (Right to Buy)F4,F5,F10$7.84Dec 11, 2017D37,500D—Jun 11, 2024Common Stock37,5000D
Stock Option (Right to Buy)F4,F5,F11$0.67Dec 11, 2017D30,826D—Jun 13, 2022Common Stock30,8260D
Stock Option (Right to Buy)F4,F5,F12$0.67Dec 11, 2017D30,827D—Jun 13, 2022Common Stock30,8270D
Stock Option (Right to Buy)F4,F5,F13$0.67Dec 11, 2017D11,969D—Jun 16, 2021Common Stock11,9690D

Explanation of responses